Circulating adipocyte fatty acid-binding protein induces insulin resistance in mice in vivo

Obesity

Volumn 23, Issue 5, 2015, Pages 1007-1013

  Kralisch, Susan ^a,b   Klöting, Nora ^b   Ebert, Thomas ^a,b   Kern, Matthias ^a   Hoffmann, Annett ^a   Krause, Kerstin ^a   Jessnitzer, Beate ^a   Lossner, Ulrike ^a,b   Sommerer, Ines ^a   Stumvoll, Michael ^a   Fasshauer, Mathias ^a,b  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; C PEPTIDE; FATTY ACID BINDING PROTEIN 4; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; FABP4 PROTEIN, MOUSE; FATTY ACID BINDING PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY COMPOSITION; BODY WEIGHT; CONTROLLED STUDY; ENERGY EXPENDITURE; FEMALE; G6PC GENE; GENE; GENE EXPRESSION; GLYCOGEN ANALYSIS; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PATHOGENESIS; PCK1 GENE; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN SECRETION; ADIPOCYTE; ADIPOSE TISSUE; ANIMAL; C57BL MOUSE; METABOLISM; OBESITY;

ANIMALIA; MUS;

ADIPOCYTES; ADIPONECTIN; ADIPOSE TISSUE; ANIMALS; BODY WEIGHT; C-PEPTIDE; FATTY ACID-BINDING PROTEINS; FEMALE; INSULIN; INSULIN RESISTANCE; MALE; MICE; MICE, INBRED C57BL; OBESITY; PPAR GAMMA;

EID: 84928587728     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.21057     Document Type: Article

References (28)

1. Rosen ED, Spiegelman BM,. Adipocytes as regulators of energy balance and glucose homeostasis. Nature 2006; 444: 847-853.
2. Kralisch S, Fasshauer M,. Adipocyte fatty acid binding protein: a novel adipokine involved in the pathogenesis of metabolic and vascular disease? Diabetologia 2013; 56: 10-21.
3. Hotamisligil GS, Johnson RS, Distel RJ, Ellis R, Papaioannou VE, Spiegelman BM,. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science 1996; 274: 1377-1379.
4. Maeda K, Cao H, Kono K, et al. Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metab 2005; 1: 107-119.
5. Makowski L, Boord JB, Maeda K, et al. Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med 2001; 7: 699-705.
6. Furuhashi M, Tuncman G, Görgün CZ, et al. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature 2007; 447: 959-965.
7. Tuncman G, Erbay E, Hom X, et al. A genetic variant at the fatty acid-binding protein aP2 locus reduces the risk for hypertriglyceridemia, type 2 diabetes, and cardiovascular disease. Proc Natl Acad Sci USA 2006; 103: 6970-6975.
8. Saksi J, Ijäs P, Mäyränpää MI, et al. Low-expression variant of fatty acid-binding protein 4 favors reduced manifestations of atherosclerotic disease and increased plaque stability. Circ Cardiovasc Genet 2014; 7: 588-598.
9. Xu A, Wang Y, Xu JY, et al. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem 2006; 52: 405-413.
10. Cao H, Sekiya M, Ertunc ME, et al. Adipocyte lipid chaperone aP2 is a secreted adipokine regulating hepatic glucose production. Cell Metab 2013; 17: 768-778.
11. Kralisch S, Ebert T, Lössner U, Jesnitzer B, Stumvoll M, Fasshauer M,. Adipocyte fatty acid binding protein is released from adipocytes by a non-conventional mechanism. Int J Obes 2014; 38: 1251-1254.
12. Schlottmann I, Ehrhart-Bornstein M, Wabitsch M, Bornstein SR, Lamounier-Zepter V,. Calcium-dependent release of adipocyte fatty acid binding protein from human adipocytes. Int J Obes 2014; 38: 1221-1227.
13. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC,. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
14. Heiker J, Klöting N, Kovacs P, et al. Vaspin inhibits kallikrein 7 by serpin mechanism. Cell Mol Life Sci 2013; 70: 2569-2583.
15. Hoffmeister A, Tuennemann J, Sommerer I, et al. Genetic and biochemical evidence for a functional role of BACE1 in the regulation of insulin mRNA expression. Obesity 2013; 21: E626-E633.
16. Sommer G, Kralisch S, Kloting N, et al. Visfatin is a positive regulator of MCP-1 in human adipocytes in vitro and in mice in vivo. Obesity (SilverSpring) 2010; 18: 1486-1492.
17. Kralisch S, Bluher M, Paschke R, Stumvoll M, Fasshauer M,. Adipokines and adipocyte targets in the future management of obesity and the metabolic syndrome. Mini Rev Med Chem 2007; 7: 39-45.
18. Maeda N, Takahashi M, Funahashi T, et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001; 50: 2094-2099.
19. Coe NR, Simpson MA, Bernlohr DA,. Targeted disruption of the adipocyte lipid-binding protein (aP2 protein) gene impairs fat cell lipolysis and increases cellular fatty acid levels. J Lipid Res 1999; 40: 967-972.
20. Shaughnessy S, Smith ER, Kodukula S, Storch J, Fried SK,. Adipocyte metabolism in adipocyte fatty acid binding protein knockout mice (aP2-/-) after short-term high-fat feeding: functional compensation by the keratinocyte fatty acid binding protein. Diabetes 2000; 49: 904-911.
21. Baar RA, Dingfelder CS, Smith LA, et al. Investigation of in vivo fatty acid metabolism in AFABP/aP2-/- mice. Am J Physiol Endocrinol Metab 2004; 288: E187-E193.
22. Garin-Shkolnik T, Rudich A, Hotamisligil GS, Rubinstein M,. FABP4 Attenuates PPARγ and adipogenesis and is inversely correlated with PPARγ in adipose tissues. Diabetes 2014; 63: 900-911.
23. Winzell MS, Nogueiras R, Dieguez C, Ahrén B,. Dual action of adiponectin on insulin secretion in insulin-resistant mice. Biochem Biophys Res Commun 2004; 321: 154-160.
24. Uysal KT, Scheja L, Wiesbrock SM, Bonner-Weir S, Hotamisligil GS,. Improved glucose and lipid metabolism in genetically obese mice lacking aP2. Endocrinology 2000; 141: 3388-3396.
25. Xu A, Tso AW, Cheung BM, et al. Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study. Circulation 2007; 115: 1537-1543.
26. Tso AW, Xu A, Sham PC, et al. Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes: a 10-year prospective study in a Chinese cohort. Diabetes Care 2007; 30: 2667-2672.
27. Tso AW, Lam TK, Xu A, et al. Serum adipocyte fatty acid-binding protein associated with ischemic stroke and early death. Neurology 2011; 76: 1968-1975.
28. Eynatten M, von Breitling LP, Roos M, Baumann M, Rothenbacher D, Brenner H,. Circulating adipocyte fatty acid-binding protein levels and cardiovascular morbidity and mortality in patients with coronary heart disease: a 10-year prospective study. Arterioscler Thromb Vasc Biol 2012; 32: 2327-2335.